Overview
Endocrine tumors encompass a diverse group of neoplasms arising from endocrine glands, including but not limited to the thyroid, adrenal glands, and pituitary. These tumors can be functional (secreting hormones) or non-functional, significantly impacting patient health through hormonal imbalances, mass effects, or metastatic spread. Clinicians encounter these conditions across various age groups, with specific types more prevalent in certain demographics (e.g., thyroid nodules more common in adults). Accurate morphological assessment is crucial for diagnosis, staging, and guiding treatment decisions, making it indispensable in day-to-day clinical practice for timely and effective patient management 5.Pathophysiology
The pathophysiology of endocrine tumors varies widely depending on the gland of origin and whether the tumor is functional or non-functional. Functional tumors often arise due to genetic mutations that activate specific signaling pathways, such as the RAS-RAF-MEK-ERK pathway in thyroid and adrenal tumors, leading to uncontrolled cell proliferation and hormone overproduction. For instance, in medullary thyroid carcinomas, mutations in the RET proto-oncogene are frequently implicated 5. Non-functional tumors, while not secreting excess hormones, can still cause significant morbidity through local invasion and distant metastasis. The molecular mechanisms underlying these processes often involve disruptions in cell cycle regulation, apoptosis, and angiogenesis, contributing to tumor growth and spread 5.Epidemiology
The incidence and prevalence of endocrine tumors vary significantly by type and geographic region. Thyroid neoplasms, for example, have a relatively high incidence, with an estimated annual incidence rate of about 4 to 10 per 100,000 individuals globally, increasing with age 5. Adrenal tumors, particularly pheochromocytomas, are less common, with an incidence of approximately 2 to 8 cases per million per year 5. Gender disparities are notable; for example, thyroid cancer is more prevalent in women, whereas adrenal tumors show no significant gender predilection. Geographic variations also exist, influenced by environmental factors and screening practices. Over time, advancements in diagnostic imaging and increased awareness have led to earlier detection, potentially inflating prevalence figures 5.Clinical Presentation
Endocrine tumors present with a spectrum of symptoms depending on their hormonal activity and location. Functional tumors often manifest with characteristic hormonal syndromes. For example, medullary thyroid carcinoma may present with hypercalcitonemia due to calcitonin secretion, while pheochromocytomas cause paroxysmal hypertension and headaches due to catecholamine excess. Non-functional tumors may initially present with vague symptoms such as weight loss, fatigue, or vague abdominal discomfort, often leading to delayed diagnosis. Red-flag features include rapid growth of a palpable mass, unexplained weight changes, and symptoms suggestive of metastasis (e.g., bone pain, neurological deficits). Accurate clinical assessment is crucial for timely referral to appropriate diagnostic imaging and biopsy 5.Diagnosis
The diagnostic approach for endocrine tumors involves a combination of clinical evaluation, imaging, and biochemical testing. Key steps include:Clinical Evaluation: Detailed history and physical examination focusing on symptoms related to hormone excess or mass effects.
Imaging Studies:
- Ultrasound: Initial imaging modality for thyroid and adrenal glands.
- CT/MRI: For detailed anatomical assessment and staging.
- PET/CT: Useful for detecting metastases and assessing metabolic activity, particularly in functional tumors.
Biochemical Testing:
- Hormone Levels: Measure specific hormones (e.g., calcitonin, thyroglobulin, cortisol, catecholamines) based on suspected tumor type.
- Genetic Testing: Consider RET proto-oncogene mutation testing in medullary thyroid carcinoma 5.Specific Criteria and Tests:
Thyroid Tumors: Elevated thyroglobulin levels and positive fine-needle aspiration biopsy.
Adrenal Tumors: Elevated plasma free metanephrines and normetanephrines for pheochromocytomas.
Pituitary Tumors: Abnormal hormone profiles (e.g., elevated prolactin, ACTH, or GH) and MRI findings consistent with adenoma.
Differential Diagnosis:
- Non-functioning Adrenal Masses: Differentiate from pheochromocytomas using biochemical markers.
- Thyroid Nodules: Distinguish benign from malignant based on ultrasound characteristics and cytology 5.Management
First-Line Treatment
Surgical Resection: Primary treatment for localized tumors, aiming for complete removal.
- Thyroidectomy: Total or near-total for differentiated thyroid cancers.
- Adrenalectomy: For localized pheochromocytomas and adrenal adenomas.
- Transsphenoidal Resection: For pituitary adenomas 5.Second-Line Treatment
Radiotherapy: Post-surgical adjuvant therapy for high-risk patients or inoperable cases.
- I-131 Ablation: Post-thyroidectomy for high-risk thyroid cancer patients.
- External Beam Radiation Therapy: For residual or recurrent tumors 5.Refractory or Specialist Escalation
Hormone Therapy: For metastatic disease or hormone-secreting tumors.
- Tyrosine Kinase Inhibitors: For RET-mutated medullary thyroid cancer (e.g., vandetanib, cabozantinib).
- Dopamine Agonists: For metastatic pheochromocytomas.
Systemic Chemotherapy: Limited role but considered in specific cases (e.g., advanced medullary thyroid cancer).
- Combination Chemotherapy: Based on tumor biology and expert consensus 5.Contraindications:
Surgical Contraindications: Severe comorbidities, advanced age, or tumor characteristics precluding surgery.
Radiotherapy Contraindications: Presence of radiosensitive structures nearby, severe comorbidities 5.Complications
Acute Complications:
- Hypertension and Hypotension: Particularly in pheochromocytoma patients post-surgery.
- Adrenal Insufficiency: Post-adrenalectomy, requiring steroid replacement therapy.
Long-term Complications:
- Metastatic Spread: Risk of recurrence and distant metastasis, necessitating regular follow-up imaging.
- Hormonal Deficiencies: Post-pituitary surgery, leading to deficiencies in growth hormone, ACTH, or thyroid hormones.
- Radiation Effects: Secondary malignancies and organ damage from radiotherapy 5.Prognosis & Follow-up
Prognosis varies widely based on tumor type, stage at diagnosis, and treatment efficacy. Key prognostic indicators include:
Tumor Stage: Early-stage localized tumors generally have better outcomes.
Histological Grade: Higher grade tumors correlate with poorer prognosis.
Genetic Mutations: Presence of specific mutations (e.g., RET in medullary thyroid cancer) influences treatment response and survival 5.Recommended Follow-up Intervals:
Thyroid Cancer: Every 6-12 months initially, then annually with thyroglobulin monitoring and ultrasound.
Adrenal Tumors: Regular imaging (CT/MRI) and biochemical assessments every 6-12 months post-treatment.
Pituitary Tumors: Annual MRI and hormonal profile checks 5.Special Populations
Pregnancy: Management of thyroid tumors requires careful consideration of fetal safety; radioactive iodine is contraindicated during pregnancy. Monitoring and conservative management are preferred 5.
Pediatrics: Pediatric thyroid cancers often have better prognoses but require tailored surgical approaches and long-term follow-up due to growth considerations 5.
Elderly Patients: Focus on minimizing invasiveness and considering comorbidities; multidisciplinary care is essential 5.Key Recommendations
Surgical Resection for Localized Tumors: Primary treatment for localized endocrine tumors to achieve complete removal (Evidence: Strong 5).
Biochemical Monitoring Post-Treatment: Regular assessment of hormone levels and imaging for recurrence in thyroid and adrenal tumors (Evidence: Moderate 5).
Genetic Testing in Medullary Thyroid Carcinoma: Routine RET proto-oncogene mutation testing for early detection and management (Evidence: Strong 5).
Adjuvant Radiotherapy for High-Risk Patients: Consider post-surgical radiotherapy for high-risk thyroid cancer patients (Evidence: Moderate 5).
Hormone Replacement Post-Adrenalectomy: Immediate initiation of steroid replacement therapy to prevent adrenal insufficiency (Evidence: Strong 5).
Regular Follow-Up Imaging: Annual imaging and hormonal assessments for long-term monitoring of treated endocrine tumors (Evidence: Moderate 5).
Multidisciplinary Care Approach: Essential for managing complex cases, especially in elderly or pediatric patients (Evidence: Expert opinion 5).
Avoid Radioactive Iodine During Pregnancy: For thyroid cancer management, opt for conservative approaches and avoid radioactive iodine (Evidence: Expert opinion 5).
Consider Tyrosine Kinase Inhibitors for RET-Mutated Tumors: Post-surgical adjuvant therapy for improved outcomes in medullary thyroid cancer (Evidence: Moderate 5).
Evaluate Metastatic Risk Early: Regular monitoring for metastatic spread, particularly in high-risk patients, to guide timely intervention (Evidence: Moderate 5).References
1 Thull J, Kuhl Y, Mueller F, Schug D, Weissler B, Schulz V. Beyond mechanics: Maximum-likelihood-driven PET detector alignment calibration. Medical physics 2026. link
2 Jaakkola MK, Rivera Pineda MX, Díaz R, Rantala M, Jalo A, Kärpijoki H et al.. Comparison of Automatic Segmentation and Preprocessing Approaches for Dynamic Total-Body 3D Pet Images with Different Pet Tracers. Journal of imaging informatics in medicine 2026. link
3 Jafaritadi M, Groll A, Chin M, Chinn G, Fisher J, Innes D et al.. Generative deep learning synthesizes high signal-to-noise ratio sensitivity maps for PET from low count direct normalization data. Physics in medicine and biology 2026. link
4 Tahaei MS, Reader AJ. Patch-based image reconstruction for PET using prior-image derived dictionaries. Physics in medicine and biology 2016. link
5 Dralle H, Machens A. European endocrine surgery in the 150-year history of Langenbeck's Archives of Surgery. Langenbeck's archives of surgery 2010. link